<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MIGLITOL</span><br/>(mig'li-tol)<br/><span class="topboxtradename">Glyset<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">antidiabetic agent</span>; <span class="classification">alpha-glucosidase inhibitor</span><br/><b>Prototype: </b>Acarbose<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg, 50 mg, 100 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Enzyme inhibition of intestinal glucosidases that delays the formation of glucose from saccharides in the small intestine.
         Miglitol does not enhance insulin secretion.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It delays the digestion of carbohydrates, lowers the postprandial hyperglycemia, and reduces the levels of glysylated hemoglobin
         (HbA<sub>1C</sub>) in type 2 diabetics.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to diet for control of type 2 diabetes; may be used alone or with a sulfonylurea.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Diabetic ketoacidosis; digestive or absorptive disorders; history of or partial intestinal obstruction, inflammatory bowel
         disease; hypersensitivity to miglitol; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to acarbose; creatinine clearance above 2 mg/dL; concomitant use with sulfonylurea; high stress conditions
         (i.e., surgery, trauma, etc.); pregnancy (category B). Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Type 2 Diabetes Mellitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 25 mg t.i.d. at the start of each meal, may increase after 48 wk to 50 mg t.i.d. (max: 100 mg t.i.d.)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give drug with first bite of each of the three main meals.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> <span class="speceff-common">Abdominal pain, diarrhea, flatulence.</span> <span class="typehead">Skin:</span> Rash. <span class="typehead">Metabolic:</span> Hypoglycemia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> <b>Miglitol</b> may reduce bioavailability of <b>propranolol,</b> <b>ranitidine;</b> <b>charcoal,</b> <b>pancreatin,</b> <b>amylase,</b> <b>pancrelipase</b> may decrease effectiveness of <b>miglitol.</b> <span class="typehead">Herbal:</span> <b>Garlic,</b> <b>ginseng</b> may potentiate hypoglycemic effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 25 mg dose is completely absorbed, amount absorbed decreases with increasing dose to where 100 mg dose is 5070%
      absorbed. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> Minimal protein binding (Metabolism: Not metabolized. <span class="typehead">Elimination:</span> Half-life 2 h; 95% excreted unchanged in urine, lower doses should be used in patients with renal impairment. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness: Indicated by improved blood glucose levels and decreased HbA<sub>1C</sub>.
         </li>
<li>Monitor for S&amp;S of hypoglycemia when used in combination with sulfonylureas, insulin, other hypoglycemia agents.</li>
<li>Lab tests: Monitor HbA<sub>1C</sub> q3mo.
         </li>
<li>Treat hypolgycemia with oral glucose (dextrose); miglitol interferes with the breakdown of sucrose (table sugar).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Keep a source of oral glucose available to treat low blood sugar; miglitol prevents digestive breakdown of table sugar.</li>
<li>Abdominal discomfort, flatulence, and diarrhea tend to diminish with continued therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>